Incruse Ellipta

Description

Incruse Ellipta
(Umeclidinium 62.5 mcg)

Description:
Incruse Ellipta is a once-daily, long-acting muscarinic antagonist (LAMA) inhaler indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It contains umeclidinium (62.5 mcg), a long-acting bronchodilator that helps to relax the muscles around the airways, making it easier to breathe. By improving airflow, Incruse Ellipta helps reduce symptoms such as shortness of breath, wheezing, and coughing, providing patients with sustained relief from COPD symptoms.

Incruse Ellipta is designed for once-daily use, offering patients a convenient and effective option for managing COPD. It is not a rescue inhaler and should not be used to treat acute symptoms or sudden breathing problems. With its simple, pre-loaded inhaler system, Incruse Ellipta ensures ease of use and consistent dosing.

Key Features:

• Long-Acting Bronchodilator: Umeclidinium (62.5 mcg) helps to relax airway muscles, improving airflow and reducing the symptoms of COPD, such as wheezing and shortness of breath.
• Once-Daily Dosing: Take one inhalation of Incruse Ellipta once a day, providing 24-hour symptom relief with just a single dose.
• Convenient Ellipta Inhaler: The Ellipta inhaler is pre-loaded, requiring no priming, making it easy to use. It delivers a precise dose of medication with each inhalation.
• COPD Maintenance: Designed to manage the long-term symptoms of COPD, Incruse Ellipta helps reduce flare-ups and improve overall lung function over time.